Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

CORIMUNO-SARI-1 (non ICU)
 
NCT04324073
RCTsarilumabstandard of careCOVID 19 hospitalizedsome concern
68/80 inconclusive
  • inconclusive 1 % increase in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
  • inconclusive 12 % increase in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias

COVID-19 severe or critically meta-analysis

Lescure (Sarilumab 200mg)
 
NCT04327388
RCTsarilumab low dose (200mg)placeboCOVID-19 severe or criticallysome concern
161/86 inconclusive
  • inconclusive 3 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
Lescure (Sarilumab 400mg)
 
NCT04327388
RCTsarilumabplaceboCOVID-19 severe or criticallysome concern
173/86 inconclusive
    Lescure (Sarilumab 400mg)
     
    NCT04327388
    RCTsarilumab high dose (400mg)placeboCOVID-19 severe or criticallysome concern
    173/86 inconclusive
      REMAP-CAP sarilumab
       
      NCT02735707
      RCTsarilumabstandard of careCOVID-19 severe or criticallyhigh
      48/402 conclusif
      • demonstrated 76 % increase in clinical improvement (PE) but with a low degree of certainty due to high risk of bias
      • suggested 86 % increase in clinical improvement (14-day) but with a low degree of certainty due to high risk of bias
      1 study excluded by filtering options (0 RCT / 1 OBS)

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).